Skip to main content
. 2019 Nov 19;20(22):5817. doi: 10.3390/ijms20225817

Figure 2.

Figure 2

Axl, MET, and miR-34a analysis. (A) WB experiments confirmed phosphorylation (upper box) and expression (bottom box) of Axl. (B) Axl/EGFR co-IP experiments revealed Axl-EGFR heterodimerization. (C) Axl (red) and EGFR (green) IF provided evidence of Axl and EGFR co-expression (yellow). (D) Axl mRNA ISH (middle column) and Axl IF (right column) assays showed both higher RNA and protein expression in two DMPMs defined as “progressed” (cases #16 and #17) than two DMPMs (cases #3 and #12). (E) MET IP/WB experiments confirmed phosphorylation (upper box) and expression (bottom box) of MET. (F) MET/EGFRco-IP experiments revealed MET-EGFR heterodimerization. (G) miRNA 34a ISH (middle column) and MET IHC (right column) assays showed both lower miRNA 34a signal levels and MET protein expression in two DMPMs defined as “progressed” (cases #16 and #17) than two DMPMs (cases #4 and #8). Legend: IP: immunoprecipitation; WB: Western blotting; IF: immunofluorescence; ISH: in situ hybridization; IHC: immunohistochemistry.